These include ripretinib, which in trial had a 15.1-month overall survival in metastatic gastrointestinal stromal tumor compared with a 6.6-month survival for patients receiving placebo, and tucatinib, which when used in combination with capecitabine and trastuzumab resulted in a mean overall survival of 21.9-months in metastatic ERBB2 (formerly HER2)–positive breast cancer compared with 17.4 months in the capecitabine and trastuzumab arm. The gene discussed is ERBB2; the disease is gastrointestinal stromal tumor.